SCHEDULE: Vivek Ramaswamy Boosts Roivant Sciences Stake to 6.8%
Beneficial Ownership Report
Vivek Ramaswamy has increased his beneficial ownership in Roivant Sciences Ltd. to 6.8% of common shares, totaling 48,428,792 shares.
Summary
- Vivek Ramaswamy, the Reporting Person, beneficially owns 48,428,792 common shares of Roivant Sciences Ltd.
- This ownership represents 6.8% of the company's common shares outstanding.
- The total beneficial ownership comprises 33,709,547 Restricted Stock Awards (RSAs) and 14,719,245 common shares underlying options exercisable within 60 days.
- The percentage ownership calculation is based on 710,210,860 common shares issued and outstanding as of November 3, 2025.
- Shares held solely by Mr. Ramaswamy's spouse, totaling 13,357,857, are not included in this beneficial ownership report.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this filing as moderately positive, as it confirms a significant and continued beneficial ownership stake by Vivek Ramaswamy, which can be interpreted as a vote of confidence in Roivant Sciences Ltd.
Positives
- A significant beneficial ownership stake by a prominent individual like Vivek Ramaswamy can signal confidence in the company's future prospects.
- The substantial holding, including RSAs and options, aligns Mr. Ramaswamy's interests with long-term shareholder value.
Negatives
- No explicit negatives are detailed in this beneficial ownership filing.
Risks
- No specific risks related to the company's operations or financial health are mentioned in this beneficial ownership filing.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that significant beneficial ownership disclosures by key individuals, especially founders or former executives, are often closely watched by the market. While this filing does not provide operational details, it confirms a substantial personal stake in Roivant Sciences Ltd., a company operating in the biopharmaceutical sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant beneficial ownership by a prominent individual may instill confidence and potentially influence investor sentiment positively.
- Management: The substantial stake held by a former executive could imply continued interest and potential influence on strategic decisions, though this filing does not detail such influence.
Key Dates
| Date | Description |
|---|---|
| 2025-11-03 | Date as of which 710,210,860 common shares were issued and outstanding, used for percentage ownership calculation. |
| 2025-11-10 | Date Roivant Sciences Ltd. filed its Form 10-Q for the quarterly period ended September 30, 2025, disclosing 695,491,615 common shares outstanding. |
| 2025-12-31 | Date of event which requires the filing of this statement (beneficial ownership as of year-end). |
| 2026-02-13 | Date this Amendment No. 6 to Schedule 13G was signed and filed. |
Recommendation
holdThe filing indicates a significant beneficial ownership by Vivek Ramaswamy, which is a positive signal of insider confidence. However, as a Schedule 13G, it does not provide operational or financial performance details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further financial disclosures to assess the company's fundamentals and future prospects.
Keywords
Roivant Sciences, Vivek Ramaswamy, Beneficial Ownership, SEC Filing, Schedule 13G, Common Shares, Biotechnology, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.